Recent Updates
Recently added Catalysts
ELAN Negative Sentiment Score: 20/100

ELANCO ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against Elanco Animal Health Incorporated, representing investors who acquired securities between November 7, 2023, and June 26, 2024. The lawsuit alleges that Elanco made materially misleading statements regarding its business and the safety of its product Zenrelia. Additionally, the company reportedly overstated its financial prospects and may delay the approval and launch of Zenrelia and Credelio Quattro. Investors affected by these issues are encouraged to contact the firm for more information.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Elanco, indicating potential legal troubles.
  • The complaint alleges that Elanco made materially false and misleading statements about its business and prospects.
  • There are concerns regarding the safety of Zenrelia, which may impact investor trust and sales.
  • Elanco's timeline for U.S. approval and commercial launch of key products may not be met.

Full Press Release Details

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Zenrelia was less safe than the Company had led investors to believe; (2) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro; (3) accordingly, the Company's business and/or financial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Elanco shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the Elanco class action lawsuit about?

The lawsuit alleges Elanco made false statements regarding its products and financial prospects.

Who can participate in the Elanco lawsuit?

All individuals and entities who acquired Elanco securities between November 7, 2023, and June 26, 2024.

What is the deadline to apply as lead plaintiff?

Investors have until December 6, 2024, to apply to become lead plaintiff.

What issues does the complaint highlight?

It highlights safety concerns about Zenrelia and delays in product approvals.

How can I contact Bragar Eagel & Squire?

You can email investigations@bespc.com or call (212) 355-4648 for inquiries.

Last updated: Dec 5, 2024